Guardion Health Sciences Announces New Viactiv Omega Boost Gel Bites Now Available for Purchase on Amazon
May 26 2022 - 9:00AM
Guardion Health Sciences, Inc. (“Guardion” or the “Company”)
(Nasdaq: GHSI) announced the availability of Viactiv Omega Boost
Gel Bites on Amazon.com. Guardion is a clinical nutrition company
that offers a portfolio of science-based, clinically-developed
products that are designed to support the health needs of
consumers, healthcare professionals and providers and their
patients. The 1,200 mg Omega-3 Gel Bites are designed to provide
total body support, including cardiovascular, brain, joint, and eye
health.
Consumers can access the product here for
purchase.
“This is an exciting milestone for our Viactiv
Omega Boost product as we are now beginning to offer the product
through third-party retail venues. Amazon is one of the top online
shopping destinations, and we look forward to continuing to expand
the opportunities for consumers to obtain this product,” commented
Bret Scholtes, Guardion’s Chief Executive Officer.
The new dosage form provides the potency of
large, hard-to-swallow soft gels in a great tasting, easy to chew
format that contains ten times more Omega-3 than the leading fish
oil gummy. The gel bite dosage form has been shown to have better
absorption and fewer digestive issues than regular soft gel
formulas, as well as no unpleasant fishy aftertaste, and no sugar,
associated with other Omega-3 products.
About Guardion Health Sciences,
Inc.
Guardion Health Sciences, Inc. (Nasdaq: GHSI),
is a clinical nutrition company. Guardion’s portfolio of
science-based, clinically developed products are designed to
support the health needs of consumers, healthcare professionals and
providers and their patients. The Company’s combination
of expertise and scientifically supported products is the
foundation of Guardion’s growing position within the clinical
nutrition marketplace. Information and risk factors with respect to
Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the U.
S. Securities and Exchange Commission (the “SEC”) at
www.sec.gov.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but are not limited to, the Company’s ability
to raise sufficient financing to implement its business plan, the
integration of a new management team, the integration of one or
more acquisitions and targets, the impact of the COVID-19 pandemic
on the Company’s business, operations and the economy in general,
the Company’s ability to successfully develop and commercialize its
proprietary products and technologies, and the Company’s ability to
maintain compliance with Nasdaq’s listing requirements. Readers are
cautioned not to place undue reliance on these forward-looking
statements, as actual results could differ materially from those
described in the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the
Company’s filings with the SEC, which are available at the SEC’s
website (www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Relations Contact:CORE IRScott
Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules AbrahamDirector
of Public RelationsCORE IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024